Kathryn Hassell
Concepts (534)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 45 | 2025 | 266 | 6.850 |
Why?
| | Water Pollutants, Chemical | 13 | 2022 | 226 | 2.180 |
Why?
| | Antiphospholipid Syndrome | 5 | 2023 | 31 | 1.780 |
Why?
| | Migraine Disorders | 2 | 2023 | 106 | 1.310 |
Why?
| | Anticoagulants | 8 | 2021 | 675 | 1.180 |
Why?
| | Perciformes | 5 | 2018 | 19 | 1.150 |
Why?
| | Heparin | 5 | 2011 | 259 | 1.100 |
Why?
| | Thrombocytopenia | 5 | 2014 | 208 | 1.080 |
Why?
| | Antibodies, Antiphospholipid | 4 | 2023 | 21 | 1.040 |
Why?
| | Fishes | 4 | 2021 | 110 | 1.020 |
Why?
| | Estrogens | 3 | 2016 | 367 | 0.800 |
Why?
| | Hydroxyurea | 5 | 2016 | 36 | 0.780 |
Why?
| | Hypertension, Pulmonary | 11 | 2025 | 1936 | 0.760 |
Why?
| | Pyridones | 2 | 2021 | 176 | 0.720 |
Why?
| | Disorders of Sex Development | 2 | 2018 | 39 | 0.690 |
Why?
| | Blood Transfusion | 7 | 2015 | 392 | 0.680 |
Why?
| | Hirudins | 4 | 2011 | 52 | 0.670 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 234 | 0.660 |
Why?
| | Hemoglobins | 8 | 2021 | 361 | 0.650 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 283 | 0.650 |
Why?
| | Testis | 2 | 2018 | 158 | 0.650 |
Why?
| | Caprylates | 1 | 2020 | 28 | 0.630 |
Why?
| | Pyrazoles | 2 | 2021 | 443 | 0.630 |
Why?
| | Alkanesulfonic Acids | 1 | 2020 | 44 | 0.620 |
Why?
| | Environmental Monitoring | 8 | 2025 | 371 | 0.600 |
Why?
| | Oocytes | 2 | 2021 | 179 | 0.580 |
Why?
| | Quality of Life | 6 | 2017 | 2999 | 0.570 |
Why?
| | Fluorocarbons | 1 | 2020 | 121 | 0.560 |
Why?
| | Neonatal Screening | 3 | 2020 | 172 | 0.540 |
Why?
| | Hemopexin | 3 | 2025 | 28 | 0.540 |
Why?
| | Cyprinidae | 1 | 2016 | 21 | 0.490 |
Why?
| | Pain | 5 | 2023 | 781 | 0.490 |
Why?
| | Australia | 10 | 2022 | 310 | 0.480 |
Why?
| | beta-Thalassemia | 2 | 2025 | 37 | 0.420 |
Why?
| | Pain Measurement | 3 | 2017 | 554 | 0.420 |
Why?
| | Embryo, Nonmammalian | 2 | 2019 | 169 | 0.420 |
Why?
| | Health Status Indicators | 1 | 2014 | 163 | 0.410 |
Why?
| | Surveys and Questionnaires | 4 | 2017 | 5929 | 0.410 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 131 | 0.400 |
Why?
| | Tricuspid Valve Insufficiency | 3 | 2011 | 26 | 0.380 |
Why?
| | Adult | 41 | 2025 | 39177 | 0.380 |
Why?
| | Humans | 76 | 2025 | 141187 | 0.370 |
Why?
| | Peptide Fragments | 4 | 2014 | 698 | 0.370 |
Why?
| | Sewage | 2 | 2025 | 33 | 0.350 |
Why?
| | Antithrombins | 2 | 2011 | 64 | 0.350 |
Why?
| | Empirical Research | 1 | 2011 | 22 | 0.340 |
Why?
| | Thrombosis | 4 | 2021 | 399 | 0.340 |
Why?
| | Nomograms | 1 | 2011 | 58 | 0.330 |
Why?
| | Male | 47 | 2025 | 69783 | 0.330 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 750 | 0.320 |
Why?
| | Censuses | 1 | 2010 | 35 | 0.320 |
Why?
| | Endocrine Disruptors | 3 | 2016 | 43 | 0.310 |
Why?
| | Animals | 28 | 2025 | 37657 | 0.310 |
Why?
| | Female | 43 | 2025 | 75515 | 0.310 |
Why?
| | Rivaroxaban | 2 | 2025 | 259 | 0.300 |
Why?
| | Vitellogenins | 3 | 2016 | 11 | 0.300 |
Why?
| | Heme | 3 | 2025 | 76 | 0.300 |
Why?
| | Health Priorities | 1 | 2009 | 44 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2025 | 337 | 0.290 |
Why?
| | Thrombophilia | 3 | 2007 | 90 | 0.290 |
Why?
| | Young Adult | 18 | 2025 | 13673 | 0.290 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2008 | 15 | 0.280 |
Why?
| | Estuaries | 2 | 2021 | 2 | 0.280 |
Why?
| | Stroke | 3 | 2021 | 1154 | 0.270 |
Why?
| | Gonads | 2 | 2018 | 23 | 0.270 |
Why?
| | Self Care | 1 | 2010 | 395 | 0.270 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2005 | 60 | 0.270 |
Why?
| | Population Surveillance | 2 | 2010 | 481 | 0.260 |
Why?
| | Nitric Oxide | 2 | 2018 | 900 | 0.260 |
Why?
| | Sickle Cell Trait | 2 | 2018 | 13 | 0.260 |
Why?
| | Hospitalists | 1 | 2011 | 248 | 0.260 |
Why?
| | Fresh Water | 3 | 2020 | 57 | 0.260 |
Why?
| | Middle Aged | 25 | 2025 | 34434 | 0.260 |
Why?
| | Haptoglobins | 2 | 2018 | 56 | 0.250 |
Why?
| | Kinetics | 2 | 2020 | 1652 | 0.250 |
Why?
| | Biodiversity | 2 | 2021 | 425 | 0.250 |
Why?
| | Phospholipids | 1 | 2008 | 221 | 0.250 |
Why?
| | Insecta | 1 | 2006 | 72 | 0.250 |
Why?
| | Estradiol | 4 | 2016 | 528 | 0.240 |
Why?
| | Environmental Pollutants | 2 | 2019 | 165 | 0.240 |
Why?
| | Fats | 1 | 2025 | 18 | 0.240 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 25 | 0.240 |
Why?
| | Patient Education as Topic | 1 | 2010 | 778 | 0.230 |
Why?
| | Iron | 3 | 2025 | 323 | 0.230 |
Why?
| | Health Services Accessibility | 3 | 2016 | 1016 | 0.230 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 668 | 0.230 |
Why?
| | Adolescent | 20 | 2025 | 22007 | 0.230 |
Why?
| | Hospitalization | 4 | 2025 | 2255 | 0.220 |
Why?
| | Estrone | 2 | 2016 | 36 | 0.220 |
Why?
| | Spleen | 2 | 2025 | 525 | 0.220 |
Why?
| | Factor Xa Inhibitors | 1 | 2025 | 175 | 0.200 |
Why?
| | Hypertrichosis | 1 | 2023 | 8 | 0.200 |
Why?
| | Cadmium | 2 | 2021 | 68 | 0.200 |
Why?
| | Hemoglobinopathies | 1 | 2023 | 5 | 0.200 |
Why?
| | Headache | 2 | 2023 | 148 | 0.200 |
Why?
| | Acromegaly | 1 | 2023 | 16 | 0.200 |
Why?
| | Antisickling Agents | 2 | 2016 | 7 | 0.200 |
Why?
| | Wetlands | 2 | 2022 | 30 | 0.200 |
Why?
| | Limb Deformities, Congenital | 1 | 2023 | 21 | 0.200 |
Why?
| | Hemostasis | 2 | 2007 | 98 | 0.190 |
Why?
| | Bays | 3 | 2017 | 7 | 0.190 |
Why?
| | Lung | 3 | 2025 | 4134 | 0.190 |
Why?
| | Child | 20 | 2024 | 22308 | 0.190 |
Why?
| | Psychometrics | 3 | 2016 | 739 | 0.190 |
Why?
| | Pesticides | 1 | 2022 | 63 | 0.190 |
Why?
| | Volatile Organic Compounds | 1 | 2023 | 61 | 0.190 |
Why?
| | Mass Screening | 1 | 2011 | 1310 | 0.190 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2892 | 0.190 |
Why?
| | Recombinant Proteins | 4 | 2011 | 1357 | 0.190 |
Why?
| | Hemolysis | 4 | 2021 | 201 | 0.180 |
Why?
| | Arginine | 2 | 2015 | 260 | 0.180 |
Why?
| | Metallothionein | 1 | 2021 | 25 | 0.170 |
Why?
| | Arterial Occlusive Diseases | 1 | 2021 | 84 | 0.170 |
Why?
| | alpha-Thalassemia | 1 | 2020 | 5 | 0.170 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2021 | 83 | 0.170 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.170 |
Why?
| | Acute Pain | 1 | 2021 | 55 | 0.170 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 152 | 0.170 |
Why?
| | Fertility Preservation | 1 | 2021 | 54 | 0.160 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2021 | 67 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 483 | 0.160 |
Why?
| | Infertility, Female | 1 | 2021 | 108 | 0.160 |
Why?
| | Ecotoxicology | 1 | 2019 | 3 | 0.160 |
Why?
| | Vascular Remodeling | 2 | 2019 | 193 | 0.160 |
Why?
| | Partial Thromboplastin Time | 2 | 2011 | 53 | 0.160 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 27 | 0.160 |
Why?
| | Aged | 11 | 2025 | 24574 | 0.160 |
Why?
| | Clove Oil | 1 | 2019 | 1 | 0.160 |
Why?
| | Eugenol | 1 | 2019 | 4 | 0.160 |
Why?
| | Iron Chelating Agents | 2 | 2011 | 19 | 0.150 |
Why?
| | Cyprinodontiformes | 1 | 2019 | 5 | 0.150 |
Why?
| | Multiple Organ Failure | 2 | 2005 | 127 | 0.150 |
Why?
| | Iron Overload | 2 | 2011 | 18 | 0.150 |
Why?
| | Benzoates | 2 | 2011 | 46 | 0.150 |
Why?
| | Liver | 3 | 2025 | 1819 | 0.150 |
Why?
| | Exercise Tolerance | 2 | 2011 | 280 | 0.150 |
Why?
| | Prospective Studies | 9 | 2025 | 7739 | 0.150 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1597 | 0.150 |
Why?
| | Hemorrhage | 2 | 2021 | 760 | 0.150 |
Why?
| | Unrelated Donors | 1 | 2019 | 38 | 0.150 |
Why?
| | Plastics | 1 | 2019 | 50 | 0.150 |
Why?
| | Altitude | 3 | 2018 | 475 | 0.150 |
Why?
| | Signal Transduction | 2 | 2013 | 5144 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3348 | 0.140 |
Why?
| | Anesthetics | 1 | 2019 | 98 | 0.140 |
Why?
| | Triazoles | 2 | 2011 | 157 | 0.140 |
Why?
| | Lipids | 2 | 2023 | 689 | 0.140 |
Why?
| | Europe | 2 | 2016 | 410 | 0.140 |
Why?
| | Aspirin | 1 | 2021 | 385 | 0.140 |
Why?
| | Bone Marrow Transplantation | 1 | 2019 | 294 | 0.140 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 270 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 209 | 0.130 |
Why?
| | Lipoproteins | 1 | 2018 | 163 | 0.130 |
Why?
| | Factor Analysis, Statistical | 2 | 2016 | 296 | 0.130 |
Why?
| | Climate Change | 1 | 2019 | 187 | 0.130 |
Why?
| | Prevalence | 4 | 2024 | 2772 | 0.130 |
Why?
| | Cohort Studies | 7 | 2018 | 5799 | 0.130 |
Why?
| | Treatment Outcome | 6 | 2025 | 11120 | 0.130 |
Why?
| | Pulmonary Artery | 4 | 2019 | 1114 | 0.130 |
Why?
| | Platelet Factor 4 | 2 | 2008 | 35 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 33 | 0.130 |
Why?
| | Zinc | 1 | 2020 | 299 | 0.130 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 254 | 0.130 |
Why?
| | Osmeriformes | 1 | 2016 | 1 | 0.130 |
Why?
| | United States | 11 | 2023 | 15220 | 0.130 |
Why?
| | Carps | 1 | 2016 | 4 | 0.130 |
Why?
| | Hypoxia | 3 | 2019 | 1164 | 0.120 |
Why?
| | Phenylketonurias | 1 | 2016 | 15 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 335 | 0.120 |
Why?
| | Asia | 1 | 2016 | 70 | 0.120 |
Why?
| | Principal Component Analysis | 2 | 2016 | 194 | 0.120 |
Why?
| | Olfactory Perception | 1 | 2016 | 16 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2019 | 623 | 0.120 |
Why?
| | Employment | 2 | 2014 | 181 | 0.120 |
Why?
| | Metals, Heavy | 1 | 2016 | 31 | 0.120 |
Why?
| | Rivers | 1 | 2016 | 65 | 0.120 |
Why?
| | Trace Elements | 1 | 2016 | 51 | 0.120 |
Why?
| | Erythrocyte Transfusion | 2 | 2015 | 202 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 852 | 0.120 |
Why?
| | Macrophages | 2 | 2023 | 1561 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2024 | 6275 | 0.120 |
Why?
| | Copper | 1 | 2016 | 114 | 0.120 |
Why?
| | Anesthesia | 1 | 2019 | 248 | 0.120 |
Why?
| | Thalassemia | 1 | 2015 | 7 | 0.120 |
Why?
| | Retrospective Studies | 8 | 2021 | 16273 | 0.120 |
Why?
| | North America | 1 | 2016 | 306 | 0.120 |
Why?
| | Lung Diseases | 2 | 2019 | 794 | 0.110 |
Why?
| | Splenic Infarction | 1 | 2014 | 1 | 0.110 |
Why?
| | Fatigue | 1 | 2017 | 338 | 0.110 |
Why?
| | Zebrafish | 1 | 2019 | 500 | 0.110 |
Why?
| | Protein S Deficiency | 1 | 1994 | 7 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Blood Component Removal | 1 | 2014 | 27 | 0.110 |
Why?
| | Complement Inactivator Proteins | 1 | 1994 | 42 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 184 | 0.110 |
Why?
| | Quality of Health Care | 2 | 2016 | 658 | 0.110 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 112 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 89 | 0.100 |
Why?
| | Thromboembolism | 1 | 2014 | 118 | 0.100 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4404 | 0.100 |
Why?
| | Leg Ulcer | 1 | 2013 | 4 | 0.100 |
Why?
| | Biomarkers | 5 | 2017 | 4174 | 0.100 |
Why?
| | Larva | 2 | 2019 | 238 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5887 | 0.100 |
Why?
| | Blood Flow Velocity | 2 | 2014 | 412 | 0.100 |
Why?
| | Ethinyl Estradiol | 1 | 2012 | 15 | 0.100 |
Why?
| | Thrombin | 2 | 2023 | 170 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 855 | 0.100 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 105 | 0.100 |
Why?
| | Venous Thrombosis | 2 | 2005 | 192 | 0.100 |
Why?
| | Sex Factors | 3 | 2019 | 2058 | 0.100 |
Why?
| | Neoplasms | 2 | 2021 | 2741 | 0.090 |
Why?
| | Racism | 1 | 2014 | 139 | 0.090 |
Why?
| | Testosterone | 1 | 2016 | 404 | 0.090 |
Why?
| | Societies, Medical | 1 | 2017 | 855 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 433 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 280 | 0.090 |
Why?
| | Preoperative Care | 2 | 2005 | 371 | 0.090 |
Why?
| | Pharmacists | 1 | 2014 | 263 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 951 | 0.090 |
Why?
| | Hemoglobin SC Disease | 3 | 1998 | 14 | 0.090 |
Why?
| | Prostheses and Implants | 2 | 2021 | 144 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2016 | 582 | 0.090 |
Why?
| | Child, Preschool | 10 | 2024 | 11457 | 0.090 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 1116 | 0.090 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 556 | 0.090 |
Why?
| | Mortality | 2 | 2012 | 358 | 0.090 |
Why?
| | Creatinine | 2 | 2014 | 489 | 0.090 |
Why?
| | Pipecolic Acids | 1 | 2011 | 26 | 0.090 |
Why?
| | Transfusion Reaction | 1 | 2011 | 62 | 0.080 |
Why?
| | Hemofiltration | 1 | 2010 | 23 | 0.080 |
Why?
| | Mice | 6 | 2025 | 18048 | 0.080 |
Why?
| | Sulfones | 1 | 2011 | 110 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 614 | 0.080 |
Why?
| | Disease Progression | 4 | 2023 | 2793 | 0.080 |
Why?
| | Awareness | 1 | 2010 | 103 | 0.080 |
Why?
| | Disease Management | 2 | 2011 | 633 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2011 | 330 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2064 | 0.070 |
Why?
| | Piperazines | 1 | 2011 | 354 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 643 | 0.070 |
Why?
| | United Kingdom | 3 | 2014 | 322 | 0.070 |
Why?
| | Career Choice | 1 | 2010 | 232 | 0.070 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 89 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 374 | 0.070 |
Why?
| | Drug Utilization Review | 1 | 2008 | 61 | 0.070 |
Why?
| | Seawater | 1 | 2008 | 31 | 0.070 |
Why?
| | Anaerobiosis | 1 | 2008 | 65 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 157 | 0.070 |
Why?
| | Pregnancy | 3 | 2005 | 7070 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7856 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2013 | 816 | 0.070 |
Why?
| | Software | 1 | 2013 | 676 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1086 | 0.070 |
Why?
| | Cost of Illness | 1 | 2010 | 312 | 0.070 |
Why?
| | Body Size | 1 | 2008 | 99 | 0.070 |
Why?
| | Depression | 1 | 2017 | 1483 | 0.070 |
Why?
| | Community Participation | 1 | 2009 | 138 | 0.070 |
Why?
| | Metabolomics | 1 | 2013 | 704 | 0.070 |
Why?
| | Lipid Peroxidation | 2 | 2018 | 150 | 0.070 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 123 | 0.070 |
Why?
| | Proteomics | 2 | 2025 | 1134 | 0.070 |
Why?
| | Deferoxamine | 1 | 2007 | 26 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2023 | 1983 | 0.060 |
Why?
| | Sulfonamides | 1 | 2011 | 520 | 0.060 |
Why?
| | Chironomidae | 1 | 2006 | 1 | 0.060 |
Why?
| | Acute Kidney Injury | 2 | 2010 | 819 | 0.060 |
Why?
| | Age Factors | 2 | 2014 | 3292 | 0.060 |
Why?
| | Registries | 2 | 2023 | 2135 | 0.060 |
Why?
| | Algorithms | 1 | 2014 | 1763 | 0.060 |
Why?
| | Rhabdomyolysis | 2 | 2018 | 24 | 0.060 |
Why?
| | Environmental Exposure | 3 | 2019 | 582 | 0.060 |
Why?
| | Urbanization | 2 | 2016 | 27 | 0.060 |
Why?
| | Social Support | 1 | 2010 | 633 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 140 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 6956 | 0.060 |
Why?
| | Coronary Angiography | 1 | 2008 | 316 | 0.060 |
Why?
| | Fibrinolysis | 2 | 1998 | 158 | 0.060 |
Why?
| | Body Weight | 2 | 2021 | 996 | 0.060 |
Why?
| | Oils | 1 | 2025 | 22 | 0.060 |
Why?
| | Dermatan Sulfate | 1 | 2005 | 4 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 565 | 0.060 |
Why?
| | Species Specificity | 1 | 2006 | 583 | 0.060 |
Why?
| | Factor V | 1 | 2005 | 24 | 0.060 |
Why?
| | Captopril | 1 | 2005 | 12 | 0.060 |
Why?
| | Waste Disposal, Fluid | 1 | 2025 | 52 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2005 | 45 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 31 | 0.060 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 64 | 0.060 |
Why?
| | Ecosystem | 2 | 2021 | 583 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1319 | 0.060 |
Why?
| | Angina, Unstable | 1 | 2005 | 78 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2172 | 0.050 |
Why?
| | Infant Mortality | 1 | 2005 | 121 | 0.050 |
Why?
| | Polysaccharides | 1 | 2005 | 87 | 0.050 |
Why?
| | Risk | 2 | 2005 | 904 | 0.050 |
Why?
| | Standard of Care | 1 | 2025 | 77 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2024 | 84 | 0.050 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2005 | 83 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 382 | 0.050 |
Why?
| | Chest Pain | 1 | 2005 | 96 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2008 | 900 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 95 | 0.050 |
Why?
| | Aerosols | 1 | 2025 | 181 | 0.050 |
Why?
| | Drug Combinations | 1 | 2005 | 358 | 0.050 |
Why?
| | Alabama | 1 | 2023 | 31 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 1008 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5200 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 2 | 2013 | 1336 | 0.050 |
Why?
| | Syndrome | 2 | 2014 | 378 | 0.050 |
Why?
| | Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| | Risk Factors | 5 | 2018 | 10438 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 321 | 0.050 |
Why?
| | E-Selectin | 1 | 2023 | 57 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 409 | 0.050 |
Why?
| | Oxygen | 1 | 2008 | 993 | 0.050 |
Why?
| | Medical Records | 1 | 2023 | 182 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 169 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2009 | 666 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 702 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 522 | 0.050 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1100 | 0.050 |
Why?
| | Agriculture | 1 | 2022 | 99 | 0.050 |
Why?
| | P-Selectin | 1 | 2021 | 28 | 0.050 |
Why?
| | Data Collection | 1 | 2024 | 661 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2025 | 585 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2794 | 0.040 |
Why?
| | Colorado | 3 | 2024 | 4610 | 0.040 |
Why?
| | Blood Pressure | 3 | 2018 | 1748 | 0.040 |
Why?
| | Dietary Exposure | 1 | 2021 | 7 | 0.040 |
Why?
| | Vitrification | 1 | 2021 | 6 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2021 | 12 | 0.040 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2021 | 7 | 0.040 |
Why?
| | Oogenesis | 1 | 2021 | 19 | 0.040 |
Why?
| | Phylogeography | 1 | 2021 | 58 | 0.040 |
Why?
| | Ovulation Induction | 1 | 2021 | 58 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 58 | 0.040 |
Why?
| | von Willebrand Factor | 2 | 1998 | 84 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1490 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 573 | 0.040 |
Why?
| | Monocytes | 1 | 2023 | 579 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2004 | 537 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 183 | 0.040 |
Why?
| | Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| | Cryopreservation | 1 | 2021 | 106 | 0.040 |
Why?
| | Metals | 1 | 2021 | 140 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 243 | 0.040 |
Why?
| | HIV Infections | 1 | 1994 | 3017 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 81 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2021 | 213 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3588 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 330 | 0.040 |
Why?
| | Rats | 2 | 2019 | 5629 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2885 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2005 | 1556 | 0.040 |
Why?
| | Proteinuria | 1 | 2018 | 99 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 63 | 0.040 |
Why?
| | Thrombomodulin | 1 | 1998 | 13 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 171 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 147 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 1330 | 0.030 |
Why?
| | Body Height | 1 | 2018 | 196 | 0.030 |
Why?
| | Victoria | 1 | 2017 | 19 | 0.030 |
Why?
| | Public Health Practice | 1 | 2017 | 69 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 771 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 715 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2016 | 9 | 0.030 |
Why?
| | Fish Proteins | 1 | 2016 | 10 | 0.030 |
Why?
| | Bile | 1 | 2016 | 25 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 169 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1010 | 0.030 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 45 | 0.030 |
Why?
| | Pilot Projects | 2 | 2016 | 1820 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 148 | 0.030 |
Why?
| | Polychlorinated Biphenyls | 1 | 2016 | 12 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1052 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 59 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 343 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5636 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 212 | 0.030 |
Why?
| | Community Health Services | 1 | 2017 | 233 | 0.030 |
Why?
| | Odorants | 1 | 2016 | 116 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2013 | 2828 | 0.030 |
Why?
| | Mononuclear Phagocyte System | 1 | 1995 | 12 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 1995 | 21 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 1995 | 12 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3709 | 0.030 |
Why?
| | Arginase | 1 | 2015 | 28 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 2016 | 118 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 287 | 0.030 |
Why?
| | Vitamin B 6 Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| | Amino Acids, Sulfur | 1 | 1994 | 8 | 0.030 |
Why?
| | Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| | beta 2-Glycoprotein I | 1 | 1994 | 5 | 0.030 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1994 | 6 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2014 | 54 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 216 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2014 | 33 | 0.030 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1994 | 9 | 0.030 |
Why?
| | Blood Coagulation | 1 | 1996 | 269 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 104 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 142 | 0.030 |
Why?
| | Interview, Psychological | 1 | 2014 | 96 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 113 | 0.030 |
Why?
| | Automation | 1 | 2014 | 100 | 0.030 |
Why?
| | Folic Acid Deficiency | 1 | 1994 | 49 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 145 | 0.030 |
Why?
| | Penicillins | 1 | 2014 | 59 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 67 | 0.030 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1994 | 80 | 0.030 |
Why?
| | Blood Platelets | 1 | 1998 | 437 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 450 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 403 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1970 | 0.030 |
Why?
| | Hematologic Tests | 1 | 1994 | 22 | 0.030 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 87 | 0.030 |
Why?
| | Homocysteine | 1 | 1994 | 154 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 103 | 0.030 |
Why?
| | Ownership | 1 | 2014 | 100 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 427 | 0.030 |
Why?
| | Smegmamorpha | 1 | 2013 | 6 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2015 | 364 | 0.030 |
Why?
| | Personnel Selection | 1 | 2014 | 86 | 0.030 |
Why?
| | Carrier Proteins | 2 | 1995 | 740 | 0.030 |
Why?
| | Catalase | 1 | 2013 | 134 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 82 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2014 | 145 | 0.030 |
Why?
| | Folic Acid | 1 | 1995 | 195 | 0.030 |
Why?
| | Mood Disorders | 1 | 2014 | 141 | 0.030 |
Why?
| | Liver Failure, Acute | 1 | 1994 | 64 | 0.030 |
Why?
| | Hemoglobin, Sickle | 1 | 2013 | 18 | 0.030 |
Why?
| | Professional Role | 1 | 2014 | 168 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 122 | 0.030 |
Why?
| | Brain Diseases | 1 | 1994 | 149 | 0.030 |
Why?
| | Permeability | 1 | 2013 | 166 | 0.020 |
Why?
| | Cysteine | 1 | 1994 | 205 | 0.020 |
Why?
| | Methylamines | 1 | 2013 | 34 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2014 | 273 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 525 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 30 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 516 | 0.020 |
Why?
| | Minority Groups | 1 | 2014 | 278 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 397 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 792 | 0.020 |
Why?
| | Glycoproteins | 1 | 1994 | 356 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2015 | 244 | 0.020 |
Why?
| | Choline | 1 | 2013 | 133 | 0.020 |
Why?
| | Perioperative Care | 1 | 2014 | 227 | 0.020 |
Why?
| | Social Behavior | 1 | 2014 | 293 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 908 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 396 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 245 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 286 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2008 | 3776 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2890 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 583 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 75 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 276 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 352 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 316 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2011 | 59 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 823 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 201 | 0.020 |
Why?
| | Public Health | 1 | 2016 | 587 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1261 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 198 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2018 | 891 | 0.020 |
Why?
| | Hemodynamics | 2 | 2011 | 1100 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 859 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1994 | 326 | 0.020 |
Why?
| | Purines | 1 | 2011 | 179 | 0.020 |
Why?
| | Communication | 1 | 2016 | 945 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3068 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 366 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 692 | 0.020 |
Why?
| | Pediatrics | 1 | 2017 | 1094 | 0.020 |
Why?
| | Walking | 1 | 2014 | 543 | 0.020 |
Why?
| | Erythrocytes | 1 | 1995 | 699 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2520 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2504 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2011 | 207 | 0.020 |
Why?
| | Pneumonia | 1 | 2015 | 656 | 0.020 |
Why?
| | Sepsis | 1 | 1995 | 616 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1444 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 625 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1491 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1859 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1662 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2007 | 10 | 0.020 |
Why?
| | Infant | 3 | 2014 | 9818 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 251 | 0.020 |
Why?
| | Calcinosis | 1 | 2008 | 238 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2087 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 150 | 0.020 |
Why?
| | Health Personnel | 1 | 2013 | 737 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2797 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1752 | 0.020 |
Why?
| | Health Services | 1 | 2007 | 118 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2070 | 0.020 |
Why?
| | Mental Disorders | 1 | 1994 | 1120 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1828 | 0.010 |
Why?
| | Program Development | 1 | 2007 | 368 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1995 | 136 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 803 | 0.010 |
Why?
| | Critical Illness | 1 | 2010 | 837 | 0.010 |
Why?
| | Isotope Labeling | 2 | 1995 | 81 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2007 | 528 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2086 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 385 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2007 | 798 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2008 | 1171 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2008 | 1225 | 0.010 |
Why?
| | Delivery of Health Care | 1 | 2007 | 961 | 0.010 |
Why?
| | Physicians | 1 | 2008 | 934 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1996 | 105 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 210 | 0.010 |
Why?
| | Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| | 4-Aminobenzoic Acid | 1 | 1995 | 8 | 0.010 |
Why?
| | Vacuoles | 1 | 1995 | 40 | 0.010 |
Why?
| | Lactobacillus | 1 | 1995 | 29 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1995 | 116 | 0.010 |
Why?
| | Reference Standards | 1 | 1995 | 186 | 0.010 |
Why?
| | Carbon Isotopes | 1 | 1995 | 143 | 0.010 |
Why?
| | Aspartic Acid | 1 | 1994 | 81 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1994 | 81 | 0.010 |
Why?
| | Deuterium | 1 | 1994 | 98 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1995 | 352 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 805 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 222 | 0.010 |
Why?
| | Cattle | 1 | 1995 | 998 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1973 | 0.000 |
Why?
| | Brain | 1 | 1994 | 2858 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|